JAN 2 7 2000

K993982

510(k) SUMMARY OF SAFETY AND EFFECTIVENESS
For Syva Emit® II Plus Monoclonal Amphetamine/Methamphetamine Assay

1. Manufacturer and Contact Information:

Manufacturer: Syva Company – Dade Behring Inc.
3403 Yerba Buena Rd.
P.O. Box 49013
San Jose, CA 95161-9013

Contact Information: Paul Rogers
Syva Company
3403 Yerba Buena Road
San Jose, CA 95161-9013
Tel: 408-239-2000

2. Device Classification Name:

The Clinical Chemistry and Clinical Toxicology Devices Panel have classified "Amphetamine Test System" as Class II.

3. Intended Use:

The Emit® II Plus Monoclonal Amphetamine/Methamphetamine Assay is a homogeneous enzyme immunoassay with a 1000 ng/mL cutoff (SAMHSA initial test cutoff level). The assay is intended for use in the qualitative and semiquantitative analyses of amphetamines in human urine.

4. Device Description and Characteristics:

This 510(k) Summary of Safety and Effectiveness is being submitted in accordance with the requirements of SMDA 1990.

The Syva Emit® II Plus Monoclonal Amphetamine/ Methamphetamine Assay is a homogenous enzyme assay intended for use in qualitative and semiquantitative analysis of amphetamines urine.

The Syva Emit® II Plus Monoclonal Amphetamine/Methamphetamine Assay has been found to be equivalent to the predicate device: Syva Emit® II Monoclonal Amphetamine/Methamphetamine Assay with regard to intended use, assay sample, and overall performance characteristics.

Comparative Analysis: The Syva Emit® II Plus Monoclonal Amphetamine/ Methamphetamine Assay showed excellent correlation to the predicate method. The comparative analysis to the predicate method resulted in complete agreement in finding samples negative and positive.

Spiked Sample Recovery: In qualitative spike analysis, the Emit® II Plus Monoclonal Amphetamine/Methamphetamine Assay using a 1000 ng/mL cutoff correctly identified the spiked specimens as being negative and positive. Known levels of methamphetamine, spiked at levels less than or equal to minus 25% of the cutoff (0 to 750 ng/mL) were consistently distinguished as negative and those spiked at levels greater than or equal to plus 25% of the cutoff (1250 to 6000 ng/mL) were consistently distinguished as positive.

The semiquantitative attribute was assessed by determining the accuracy of recovery for analyte-spiked samples by the Emit® II Plus Monoclonal Amphetamine/Methamphetamine Assay. Negative human urine specimens were spiked with concentrations of d-methamphetamine at levels throughout the semiquantitative range of 500 to 1800 ng/mL. For each known concentration, drug recovery was calculated using the average concentration obtained by the Emit® II Plus Monoclonal Amphetamine/Methamphetamine Assay. Within this range, recovery ranged up to ± 9% of nominal concentrations of spiked analyte.

Precision: A precision study was performed using Syva Emit® II Plus Monoclonal Amphetamine/Methamphetamine Assay in both the qualitative and semiqualitative modes. Acceptable within-run and total precision statistics for both the qualitative and semiquantitative assays were observed.

Qualitative results, determined from rates for controls and cutoff calibrator, demonstrated within-run precision with coefficients of variation (CV) of 0.4% and total precision with CV ranging from 0.7 – 0.9%.

Semiquantitative results, determined from concentrations for controls and cutoff calibrator, demonstrated within-run precision with CV ranging from 1.2 – 1.9% and total precision with CV ranging from 2.4 – 4.3%.

Sensitivity: The sensitivity level of the Emit® II Plus Monoclonal Amphetamine/Methamphetamine Assay is less than 500 ng/mL. This level represents the lowest concentration of amphetamines that can be distinguished from 0 ng/mL with a confidence level of 95%.

5. Substantial Equivalence:

In conclusion, Syva Company -- Dade Behring Inc. considers the Syva Emit® II Plus Monoclonal Amphetamine/Methamphetamine Assay to be substantially equivalent to the Emit® II Monoclonal Amphetamine/Methamphetamine Assay with regard to intended use, assay sample, and overall performance characteristics.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

JAN 2 7 2000

Mr. Paul L. Rogers, Jr.
Senior Manager, Regulatory Affairs
Syva Company – Dade Behring Inc.
3403 Yerba Buena Road
P.O. Box 49013
San Jose, California 95161-9013

Re: K993982
Trade Name: Syva Emit® II Plus Monoclonal Amphetamine/Methamphetamine Assay
Regulatory Class: II
Product Code: LAF, DZK
Dated: November 22, 1999
Received: November 24, 1999

Dear Mr. Rogers:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Steven Gutman

Steven I. Gutman, M.D., M.B.A.
Director
Division of Clinical Laboratory Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

K993982

Device Name: Syva Emit® II Plus Monoclonal Amphetamine/Methamphetamine Assay

Indications for Use:

The Emit® II Plus Monoclonal Amphetamine/Methamphetamine Assay is a homogeneous drugs-of-abuse enzyme immunoassay with a 1000 ng/mL cutoff (SAMHSA initial test cutoff level). The assay is intended for use in the qualitative and semiquantitative analyses of amphetamines in human urine. Emit® II Plus assays are designed for use with a number of chemistry analyzers.

The Emit® II Plus Monoclonal Amphetamine/Methamphetamine Assay provides only a preliminary analytical test result. A more specific alternative chemical method must be used to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Other chemical confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug-of-abuse test result, particularly when preliminary positive results are used.

Jean Cooper
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K993952

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓ OR Over-The-Counter Use _____
(Per 21 CFR 801.109)

(Optional Format 1-2-96)